PAYS Earnings

PAYS reported its earnings on 2026-05-12, showcasing a revenue of against an estimate of 27.05M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.16 by 0%. The stock experienced a -12.33% price change on the earnings day and a -11.8% change over the next five days, reflecting market reactions to the results.

Following PAYS's earnings announcement on 2026-05-12, the stock price moved by -12.33% on the day of the release. Over the subsequent five days, it saw a -11.8% change. Historically, PAYS's stock price tends to shift by an average of -2.72% in the 10 days leading up to earnings and 4.25% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate PAYS's annual revenue to reach 23.92M, while the EPS is projected at 0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PAYS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PAYS's stock price typically moves by -2.72% in the 10 days before its earnings and 4.25% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.04 and revenue of 23.92M.

The earnings call reveals strong financial performance with significant revenue growth in patient affordability and plasma segments, improved gross profit margins, and increased income before taxes. The Q&A session highlights confidence in future program additions and capacity to handle growth, although some uncertainty exists regarding non-pharmaceutical programs and FDA approval. Operating expenses are well-managed, and despite no share repurchases, cash reserves are earmarked for strategic uses. The overall sentiment is positive, with expectations for continued revenue growth and operational efficiency.